Rize Oncology Inc.
CNSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 144.40K | 218.80K | 123.50K | 156.90K | 171.70K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 231.10K | 217.30K | 367.00K | 404.20K | 267.10K |
| Operating Income | -231.10K | -217.30K | -367.00K | -404.20K | -267.10K |
| Income Before Tax | -232.50K | -215.00K | -370.00K | -400.90K | -265.60K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -232.50K | -215.00K | -370.00K | -400.90K | -265.60K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -232.50K | -215.00K | -370.00K | -400.90K | -265.60K |
| EBIT | -231.10K | -217.30K | -367.00K | -404.20K | -267.10K |
| EBITDA | -192.60K | -152.10K | -- | -- | -- |
| EPS Basic | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 80.74M | 80.39M | 75.74M | 75.74M | 72.93M |
| Average Diluted Shares Outstanding | 80.74M | 80.39M | 75.74M | 75.74M | 72.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |